BSE filing, NSE: JLHL. Summary written from the filing by ALFA Finder's alert engine.
Jupiter Life Line Hospitals Ltd: key numbers
- Share price
- ₹256.75
- Market cap
- ₹8,417 Cr
- Revenue (annual)
- ₹1,500 Cr
- Net profit (annual)
- ₹194.0 Cr
- P/E (TTM)
- 45.1×Sector 52.0×
- Promoter holding
- 40.91%+0.00% QoQ
- FII holding
- 9.13%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Jupiter Life Line Hospitals Ltd
All →Jupiter Life Line Hospitals Earnings Call Transcript: Key Takeaways
Jupiter Lifeline reports strong growth with Q2 revenue of ₹456.5 Cr and EBITDA of ₹106.9 Cr. Management prioritizes asset ownership, recently acquiring the Pune South hospital land for ₹150 Cr.
Jupiter Life Line Hospitals Acquisition Worth ₹150 Cr
Jupiter Life Line Hospitals executed a sale agreement to acquire 11,452.07 sq m of land in Pune for Rs 150 Crore. The land is where its South Pune hospital project is under development.
- Value
- ₹150.0 Cr
Jupiter Life Line Hospitals Capacity Expansion: ₹0.01 Cr Investment
Jupiter Life Line Hospitals will hold 100% of newly incorporated subsidiary Holitti Private Limited, a healthcare services entity. The subscription is for paid-up capital of Rs 1,00,000, about Rs 0.01 Crore.
- Value
- ₹0.01 Cr
Jupiter Life Line Hospitals Merger & Restructuring Worth ₹0.01 Cr
Jupiter Life Line Hospitals will incorporate wholly owned subsidiary Holitti Private Limited for healthcare services, subscribing Rs 1 lakh. It will run laboratory and healthcare services.
- Value
- ₹0.01 Cr
Jupiter Life Line Hospitals Investor Presentation: Key Takeaways
Q2FY27 revenue Rs 436.3 cr (+15.8% YoY), EBITDA Rs 106.9 cr (23.4% margin), PAT Rs 56.4 cr (-1.7%) on Dombivli ramp-up, depreciation and finance costs. Bed capacity expanding from 1,700 to 2,900.
Jupiter Life Line Hospitals Q2 FY27 Results: Net Profit ₹56.4 Cr, Down 1.9% YoY
Jupiter Life Line Hospitals Ltd reported revenue from operations of ₹456.5 Cr (+16.0% YoY) and net profit of ₹56.4 Cr (-1.9% YoY) for Q2 FY27.
- Key figure
- Net profit ₹56.4 Cr · -1.9% YoY
Other board meeting date announcements
All →Patel Engineering Board Meeting Date
Patel Engineering has scheduled its Board meeting for November 5, 2026, to approve Q1 and H1 FY27 unaudited results. No financial figures or decisions are reported in this advance notice.
GKB Ophthalmics Board Meeting Date
GKB Ophthalmics scheduled its Board Meeting for November 12, 2026. The meeting will consider approving unaudited results for the September 30, 2026 quarter and half year.
Bombay Oxygen Investments Board Meeting Date
Board meeting scheduled for Nov 6, 2026 to approve Q1 and H1 FY27 unaudited results. Trading window closed for insiders Oct 1–Nov 8, 2026.
OCCL Board Meeting Date
OCCL Ltd has scheduled its Board meeting for 6 November 2026 to consider Q1 FY27 unaudited results and a possible interim dividend. The trading window for designated persons closed from 1 October 2026.
TCM Board Meeting Date
TCM Limited intimated a Board meeting for 06/11/2026 to approve Q2 FY27 results. The trading window will reopen 48 hours after the results declaration.
Mercury Laboratories Board Meeting Date
Mercury Laboratories scheduled its Board meeting for November 5, 2026, to approve Q2/H1 FY27 results. Trading window remains closed until 48 hours post-announcement.